StockNews.com Begins Coverage on Ekso Bionics (NASDAQ:EKSO)

StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report released on Monday. The brokerage issued a hold rating on the stock.

Other analysts also recently issued research reports about the company. Lake Street Capital started coverage on Ekso Bionics in a research report on Monday, June 24th. They issued a buy rating and a $2.50 price objective for the company. HC Wainwright reiterated a buy rating and issued a $10.00 price objective on shares of Ekso Bionics in a research report on Tuesday, July 30th.

Ekso Bionics Price Performance

NASDAQ EKSO opened at $1.23 on Monday. Ekso Bionics has a twelve month low of $0.62 and a twelve month high of $3.13. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.77 and a current ratio of 2.42. The stock has a market capitalization of $22.68 million, a PE ratio of -1.27 and a beta of 1.45. The stock has a 50-day simple moving average of $1.12 and a 200 day simple moving average of $1.23.

Ekso Bionics (NASDAQ:EKSO) last posted its quarterly earnings data on Monday, July 29th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. The business had revenue of $4.95 million for the quarter, compared to analyst estimates of $5.34 million. During the same period in the prior year, the firm posted ($0.31) EPS. Research analysts anticipate that Ekso Bionics will post -0.42 EPS for the current year.

Institutional Trading of Ekso Bionics

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC increased its stake in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 596,050 shares of the company’s stock after buying an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 at the end of the most recent reporting period. 6.42% of the stock is currently owned by hedge funds and other institutional investors.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.